Plunkett Research Online: Palvella Therapeutics Inc

PALVELLA THERAPEUTICS INC (PVLA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based o.....



Palvella Therapeutics Inc
Ticker: PVLA
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 484 253-1461
Fax:
Address: 125 Strafford Avenue
Suite 360
Wayne, PA 19087 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
Contacts Description
Wesley KaupinenCEO/Director/Founder/President
Matthew KorenbergCFO
See More
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based o.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
20232022
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: